Hyperkalemia in chronic heart failure with renal dysfunction or diabetes mellitus: Results from the TREAT HF study.
Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, vol.49, pp.198-205, 2021 (ESCI, Scopus, TRDizin)
- Publication Type: Article / Article
- Volume: 49
- Publication Date: 2021
- Doi Number: 10.5543/tkda.2021.58675
- Journal Name: Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
- Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Central & Eastern European Academic Source (CEEAS), EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
- Page Numbers: pp.198-205
- Keywords: Hyperkalemia, heart failure, diabetes mellitus, chronic kidney disease, CONVERTING-ENZYME-INHIBITORS, VENTRICULAR SYSTOLIC FUNCTION, SERUM POTASSIUM, PREDICTORS, RISK, ASSOCIATION, CANDESARTAN, ALISKIREN, OUTCOMES
- Eskisehir Osmangazi University Affiliated: Yes
Abstract
Objective: Chronic kidney disease (CKD) and diabetes mellitus (DM) are common comorbidities in heart failure (HF). Patients with HF are at a high risk of hyperkalemia, and are therefore undertreated with respect to disease-modifying therapies. The Turkish Research Team-Heart Failure (TREAT HF) data were analyzed for the evaluation of hyperkalemia in real-life clinical practice in HF patients with CKD or DM.